The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Imprimis NJOF, situated at 1705 US-46, Suite 6B, Ledgewood, NJ 07852 bearing FEI Number 3013024146 has made the decision to recall Epinephrine/Lidocaine (0.25 mg/mL, 7.5 mg/mL) Sterile Ophthalmic Injection (Epi-Lido) and Tropicamide-Proparacaine-Phenylephrine-Ketorolac (1%, 0.5%, 2.5%, 0.5%) Sterile Ophthalmic Solution (Mydriatic-4).This recall is for a total of two unexpired lots of products due to subpotent API levels at stability timepoints.

Product	*Lot Number*	*Date Compounded*	*Expiry Date*	*Quantity Released*	*Reason for Recall*
Epi-Lido	*24DEC017*	*01/14/2025*	*07/12/2025*	*6,880 units*	*Subpotent **Epinephrine** levels (<90%) at the 120-day stability timepoint. Potency specifications for Epi-Lido are between 90.0-110.0%, and we recently identified a stability batch that had subpotent Epinephrine assay levels of 88.3%. The subpotent Epinephrine may result in reduced effectiveness when used on patients.*
Mydriatic-4	*25MAR032*	*03/19/2025*	*07/16/2025*	*2890 units*	*Subpotent **Proparacaine** levels (<90%) at the day 90 stability timepoint. Potency specifications for Mydriatic-4 are between 90.0-110.0%, and we recently identified a stability batch that had subpotent Proparacaine assay levels of 89.7%. The subpotent Proparacaine may result in reduced effectiveness when used on patients.*